Fabrazyme Safe, Effective in Japanese Study

Fabrazyme Safe, Effective in Japanese Study

295317

Fabrazyme Safe, Effective in Japanese Study

Fabrazyme (agalsidase beta) demonstrated an acceptable safety profile and resulted in sustained reductions in globotriaosylceramide (GL-3) levels over seven years among patients with Fabry disease, a large real-world study from in Japan found.  The study, “Long-term safety and efficacy of agalsidase beta in Japanese patients with Fabry disease: aggregate data from two post-authorization safety studies,” was published in the journal Expert Opinion on Drug Safety.  Fabry disease is caused by a lack of alpha-galactosidase A,…

You must be logged in to read/download the full post.